• The Korean Journal of Applied Statistics
• /
• v.31 no.4
• /
• pp.427-446
• /
• 2018

Korea will have a super-aged society within only 30 years according to the United Nations' definition of an aging society and the statistics on Korea's Population projections (2016), indicates that Korea has the fastest ageing speed in the world. There is a lack of data on long-term time-series data on death as related to pension and welfare policies compared to the rapid rate of aging. This paper estimates life expectancy over 245 years (from 1955 to 2200) through past and future forecasts as well as compares the expected life expectancy of the synthetic cohort and the real cohort. In addition, an international comparisons were made to understand the level of aging in Korea. Estimates of the back-projection period were compared with previous studies and the LC model to improve accuracy and objectivity. In addition, the predictions after 2016 reflected the declined mortality rate effect of Korea using the LC-ER model. The results showed an increase in life expectancy of about 30 years over 60 years (1955-2015) with an expected life expectancy of the real cohort over the second century (1955-2155) higher than the synthetic cohort. The comparative advantage of life expectancy of real cohorts was confirmed to be a common trend among comparative countries. In addition, Japan and Korea have a higher life expectancy and starting from 85 to 90 years old, all comparative countries show that the growth rate for the life expectancy of synthetic and real cohorts is less than previous years.

• Clinical and Experimental Pediatrics
• /
• v.62 no.5
• /
• pp.155-161
• /
• 2019

Following the first successful trial of surfactant replacement therapy for preterm infants with respiratory distress syndrome (RDS) by Fujiwara in 1980, several animal-derived natural surfactants and synthetic surfactants have been developed. Synthetic surfactants were designed to overcome limitations of natural surfactants such as cost, immune reactions, and infections elicited by animal proteins contained in natural surfactants. However, first-generation synthetic surfactants that are protein-free have failed to prove their superiority over natural surfactants because they lack surfactant protein (SP). Lucinactant, a second-generation synthetic surfactant containing the SP-B analog, was better or at least as effective as the natural surfactant, suggesting that lucinactant could act an alternative to natural surfactants. Lucinactant was approved by the U. S. Food and Drug Administration in March 2012 as the fifth surfactant to treat neonatal RDS. CHF5633, a second-generation synthetic surfactant containing SP-B and SP-C analogs, was effective and safe in a human multicenter cohort study for preterm infants. Many comparative studies of natural surfactants used worldwide have reported different efficacies for different preparations. However, these differences are believed to due to site variations, not actual differences. The more important thing than the composition of the surfactant in improving outcome is the timing and mode of administration of the surfactant. Novel synthetic surfactants containing synthetic phospholipid incorporated with SP-B and SP-C analogs will potentially represent alternatives to natural surfactants in the future, while improvement of treatment modalities with less-invasive or noninvasive methods of surfactant administration will be the most important task to be resolved.